NEW YORK — IMIDomics said on Monday that it has partnered with drug developer Gossamer Bio on the discovery and development of new treatments for immune-mediated inflammatory diseases (IMID), beginning with inflammatory bowel disease.
IMIDomics has developed a platform that analyzes clinical and molecular data derived from an immune-mediated inflammatory disease biobank at Vall d’Hebron University Hospital in Spain to generate insights into disease biology.
Under the terms of the deal, Gossamer may select specific projects on which to collaborate with IMIDomics, beginning with IBD. Additional terms were not disclosed.
"IMIDomics … [has] assembled a unique and world-class platform for clinical and molecular profiling of IMID patients, biobanking, and analytics," Gossamer CSO Luisa Salter-Cid said in a statement. "Their platform will drive a deeper understanding of IMID patients and disease biology, which we hope will inform our strategy for drug discovery and development."
In 2017, Barcelona, Spain-based IMIDomics began working with Celgene on the development of new immune-mediated inflammatory disease drugs.